加载中
NASDAQHealthcareMedical - Devices
最新数据
US$1.075
−US$0.045 · -4.02%
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
收盘时
US$1.075
−US$0.045 · -4.02%
盘后
US$1.04
−US$0.035 · -3.26%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
日内区间
当前US$1.075
52周区间
当前US$1.075
盘中时间采用ET。市场数据可能有所延迟。
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
日内区间
当前US$1.075
52周区间
当前US$1.075
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1209.77万 USD | 345.3万 USD | 195.24万 USD | 17.12万 USD | 17.81万 USD |
| 销货成本 | 395.63万 USD | 237.33万 USD | 149.59万 USD | 24.2万 USD | 27.59万 USD |
| 毛利 | 814.14万 USD | 107.97万 USD | 45.65万 USD | −7.08万 USD | −9.77万 USD |
| 研究与开发 | 498.34万 USD | 506.52万 USD | 694.07万 USD | 492.94万 USD | 392.5万 USD |
| 销售、一般及管理费用 | 738.45万 USD | 790.17万 USD | 692.63万 USD | 697.94万 USD | 626.03万 USD |
| 营业费用 | 1236.79万 USD | 1296.69万 USD | 1241.18万 USD | 996万 USD | 1012.05万 USD |
| 利息支出 | 33.41万 USD | 22.9万 USD | — | — | 3053 USD |
| 折旧和摊销 | 26.17万 USD | 24.68万 USD | 19.93万 USD | 11.86万 USD | 8.07万 USD |
| 营业利润 | −422.65万 USD | −1188.72万 USD | −1195.53万 USD | −1003.08万 USD | −1021.82万 USD |
| 净利润 | −360.54万 USD | −1231.81万 USD | −1185.95万 USD | −999.96万 USD | −994.82万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.00
上涨空间 365.12%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年4月16日 | 1:6 | — | — |
股票拆分 | 2021年4月1日 | 1:3 | — | — |
已生效 2026年4月16日
1:6
已生效 2021年4月1日
1:3
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
